Trial Profile
A Phase 2, Randomized, Open-Label, Crossover Study to Compare DM-1992, a Novel Gastric-Retentive Extended-Release Formulation of Levodopa/Carbidopa, to an Immediate-Release Carbidopa Tablet in Patients With Advanced Parkinson's Disease With Motor Fluctuations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2018
Price :
$35
*
At a glance
- Drugs Levodopa/carbidopa (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- Sponsors Assertio Therapeutics; Depomed
- 20 Jun 2013 Results presented at the 17th International Congress of Parkinson's Disease and Movement Disorders
- 07 Nov 2012 Primary endpoint 'Off-time' has been met.
- 05 Jul 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.